Leerink gave the firm an "Outperform" rating with an $18 price target while Canaccord gave it a "Buy" rating with a $17 price target.
A new study in Nature Chemistry illustrates why PCR, NGS, and microarray firms are interested in incorporating the startup's workflow into their products.
The multiplexed qPCR test can detect and differentiate four Dengue serotypes in a single reaction tube and is designed for both diagnosis and surveillance.
NanoString will develop a companion diagnostic for Merck's anti-PD-1 immunotherapy based on immune-related gene expression signatures.
The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.
In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.